Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from November 22, 2025

Partial Published before the outcome was known, scored automatically when the window closed on February 20, 2026.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted
$34.71 Published $46.51 Target $15.63 Window close $40.99 Peak
$33.00 – $36.00Entry zone — fair-value band
$34.71Published — price the day we called it
$46.51Target — the price the thesis aimed for
$40.99Peak — highest point inside the window, not a realized return
$15.63Window close — end-of-window price, context only

What happened

Partial

Reached 53% of the predicted growth at its peak, without hitting the target.

Peak price
$40.99
peak on December 5, 2025 — not a realized return
Peak gain
+18.1%
peak, from the publication price
Window close
$15.63
end-of-window price, context only
Days to target
—
Window
November 22, 2025 – February 20, 2026

The thesis — published November 22, 2025

Predicted growth
+34%
over the measurement window
Target price
$46.51
the price the thesis aimed for
Entry zone
$33.00 – $36.00
the fair-value band we waited for
Price at publication
$34.71
published November 22, 2025
Confidence
63%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Hims & Hers is a fast-growing telehealth company that recently fell sharply after a strong run. Its price is well below the recent average and it looks oversold, but investor interest is still solid. With no new news, this looks like a short-term rebound setup over the next three months for aggressive traders; keep positions modest because it can swing a lot.

Primary drivers

  • Online direct-to-consumer health services with fast sales growth
  • Big price pullback below the recent average creates rebound chance
  • Investor interest stays strong despite the recent decline
  • Valuation and scaling risk mean smaller, actively managed positions

How it played out

HIMS: rebound faded before the target

Lyra published HIMS at $34.71 on 2025-11-22 as a short-term rebound setup. The expected growth was 34%. The thesis pointed to fast growth in online direct-to-consumer health services, a big pullback below the recent average, still-solid investor interest, and valuation and scaling risk that called for smaller, actively managed positions.

Inside the window, HIMS rose to $40.99 on 2025-12-05, a peak gain of 18.1%. It stayed below the $46.51 target and never reached it. By 2026-02-20, it ended at $15.63. The rebound partly appeared early, but the published thesis did not play out through the full window.

What happened during the window

On 2026-02-19, Hims & Hers announced an agreement to acquire Eucalyptus in a $1.15 billion deal. The company said the deal would expand its reach into Australia and Japan and deepen its presence in the UK, Germany, and Canada.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals